We showed that combining eIF4A inhibition with the FDA-approved XPO1 inhibitor selinexor resulted in a potent synergistic effect in cell culture and in profound tumor growth suppression and extended survival in both orthotopic and patient-derived xenograft models. This evidence concerns the gene XPO1 and neoplasm.